Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Ad-REIC/Dkk-3

REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.

Trial Locations (1)

10029

Mount Sinai School of Medicine, New York

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

Momotaro-Gene Inc.

INDUSTRY

NCT01197209 - Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer | Biotech Hunter | Biotech Hunter